Welcome to our dedicated page for Grifols SA SEC filings (Ticker: GRFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Grifols, S.A. filings document the company's foreign-private-issuer disclosures, including Form 6-K reports furnished under the Exchange Act and annual financial materials prepared for its Spanish-listed healthcare group. The filings describe operating results for Biopharma and other activities, product performance in immunoglobulins and plasma-derived medicines, margins, cash flow, leverage and liquidity.
Regulatory documents also cover capital-structure actions such as debt refinancing, note redemptions, revolving credit facilities and dividend approvals. Other filings record board and secretary appointments, audited financial statements, risk and uncertainty statements, inside-information notices, shareholder capital details and the governance framework surrounding Grifols' Class A and Class B shares.
Grifols, S.A. reported first-half 2026 revenue of €3,574 million, up 2.6% on a constant-currency basis, driven mainly by Biopharma, which grew 5.4% cc with immunoglobulins up 12.8%. Adjusted EBITDA was €854 million, with a 23.9% margin, while group profit rose 28.7% to €227 million.
Free cash flow pre-M&A improved to a positive €91 million from a negative €12 million, and the net leverage ratio stood at 4.2x with liquidity of €2,030 million. Grifols refinanced all 2027 maturities via an upsized c.€3 billion Term Loan B and an expanded revolving credit facility of over $2 billion, and redeemed €500 million of a 2030 bond, leaving no significant maturities until the fourth quarter of 2028. Credit ratings were upgraded by S&P to BB- with a stable outlook and improved by Moody’s and Fitch, and full-year 2026 guidance is confirmed.
Grifols, S.A. reports an update to the composition of its Board of Directors following an extraordinary board meeting held on 19 June 2026. The board is chaired by independent director Susana González Rodríguez, with independent members Pascal Ravery and Anne-Catherine Berner, and proprietary members Albert Grifols Coma-Cros and Raimon Grifols Roura. Núria Martín Barnés serves as non‑member secretary, and Laura de la Cruz Galán is identified as Secretary to the Board of Directors.
Grifols, S.A. reports that its Ordinary General Shareholders' Meeting approved cash distributions and multiple governance and capital measures for the 2025 fiscal year. Shareholders backed a preferred dividend of EUR 0.01 per Class B share and an ordinary dividend of EUR 56,065,663, both payable on 2 July 2026.
The meeting also approved audited 2025 accounts, re-elected Deloitte as group auditor for 2027–2029, renewed two independent directors and adjusted board regulations and the directors’ remuneration policy. Shareholders authorised share capital increases of up to 50% over five years, treasury share acquisitions and a capital reduction of up to 10% of current share capital via redemption of treasury shares.
Grifols, S.A. has called its Ordinary General Shareholders' Meeting, with first call on June 17, 2026 and the meeting expected to be held on second call on June 18, 2026 at 12:00 p.m. CET at its registered office in Sant Cugat del Vallès, Barcelona.
Shareholders may attend in person or by telematic means, use distance voting and delegation mechanisms, and participate via a Shareholders' Electronic Forum on the corporate website. All shareholders may attend if their shares are registered at least five days before the meeting, but only holders of Class A shares may vote on agenda items. The company details procedures for registration, remote participation, information requests, and privacy, and will provide a free shuttle service on June 18, 2026 between the Sant Joan station and the meeting venue.
Brandes Investment Partners reports beneficial ownership of Grifols Class B shares totaling 27,220,179 ORD and 36,343,419 ADRs, representing 24.31% of the class as of 03/31/2026.
The amendment (Amendment No. 6) to the Schedule 13G/A updates the registrant's holdings and shows shared dispositive power over those shares. The filing is signed by an Executive Director on 05/06/2026.
Grifols, S.A. files its Form 20-F annual report for the year ended December 31, 2025, presenting IFRS-IASB financials in millions of euros. Net revenue was €7,524 million versus €7,212 million in 2024, or €7,718 million on a constant-currency basis, reflecting 7.0% growth excluding exchange effects.
Immunoglobulin products remain central, contributing 54.3% of 2025 net revenue. The company highlights high leverage: as of December 31, 2025, current and non-current financial liabilities totaled €9.6 billion, including €9.1 billion of long-term debt, with part of its borrowings at variable interest rates.
The report explains previously disclosed accounting corrections for the Biotek America LLC joint operation and the Shanghai RAAS investment, which adjusted 2022–2023 figures but are now fully incorporated with no additional errors identified in 2025. Extensive risk disclosures cover indebtedness, plasma supply, manufacturing complexity, regulatory compliance, geopolitical tensions, tax changes and the early use of artificial intelligence.
Grifols, S.A. has completed a major refinancing of its 2027 debt, replacing existing borrowings with a new Term Loan B package and revolving credit facility. The new structure includes a USD 2.0 billion dollar term loan, a EUR 1.25 billion euro term loan, and a USD 2.065 billion revolving credit facility.
The term loans mature in seven years and the revolver in six and a half years, extending the company’s debt schedule. Pricing is set at SOFR + 250 basis points for the dollar tranche and Euribor + 300 basis points for the euro tranche, with small original issue discounts and leverage-based margin step-downs. Grifols will use the proceeds to repay its 2019 TLB facilities, redeem remaining 2019 notes, and, together with a separate EUR 500 million notes redemption, lower funded gross debt, reduce cash interest costs, and strengthen its balance sheet while maintaining liquidity.
Grifols, S.A. reports that its Board of Directors has decided to start a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary that is the parent of its U.S. Biopharma business. The company stresses that any IPO would depend on regulatory and legal requirements, internal approvals and market conditions, and there is no assurance that it will be undertaken or completed. Grifols also notes that, regardless of whether any IPO occurs, its shares will continue trading in Spain on the mercado continuo, and this communication does not constitute an offer or solicitation to buy or sell securities.